Biofrontera Inc. Files 8-K Current Report

TL;DR

BFRI filed an 8-K, standard SEC update, check for details.

AI Summary

Biofrontera Inc. filed an 8-K on November 22, 2024, reporting on its current status. The filing primarily serves as a notification of events and includes financial statements and exhibits. No specific material events or financial updates were detailed in the provided excerpt.

Why It Matters

This filing indicates Biofrontera Inc. is providing updates to the SEC, which is standard for publicly traded companies and may contain important disclosures for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.

Key Players & Entities

• Biofrontera Inc. (company) — Registrant
• November 22, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-40943 (filing_id) — SEC File Number
• 47-3765675 (tax_id) — IRS Employer Identification No.
• 120 Presidential Way, Suite 330 Woburn, Massachusetts 01801 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar
• $4.2 million — completion of a private placement of a $4.2 million senior secured convertible note (the "N

Filing Documents

• form8-k.htm (8-K) — 45KB
• ex99-1.htm (EX-99.1) — 11KB
• 0001493152-24-047306.txt ( ) — 285KB
• bfri-20241122.xsd (EX-101.SCH) — 4KB
• bfri-20241122_def.xml (EX-101.DEF) — 30KB
• bfri-20241122_lab.xml (EX-101.LAB) — 36KB
• bfri-20241122_pre.xml (EX-101.PRE) — 27KB
• form8-k_htm.xml (XML) — 7KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 120 Presidential Way , Suite 330 Woburn , Massachusetts 01801 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 245-1325 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the "Exchange Act") (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On November 22, 2024, Biofrontera Inc. issued a press release announcing the successful completion of a private placement of a $4.2 million senior secured convertible note (the "Note") with its two majority shareholders. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. 99.1 Press release dated November 22, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November 22, 2024 Biofrontera Inc. (Date) (Registrant) /s/ E. Fred Leffler III E. Fred Leffler, III Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR